CN Patent

CN119462616A — 化合物的盐及其晶型

Assigned to Hutchmed Ltd · Expires 2025-02-18 · 1y expired

What this patent protects

本发明涉及化合物的盐及其晶型。更具体地，本发明属于药学领域，提供了化合物4‑氯‑3‑(2‑(2‑((4‑((3S,5R)‑3,5‑二甲基哌嗪‑1‑基)苯基)氨基)嘧啶‑5‑基)乙基)‑5‑甲氧基‑N‑甲基苯甲酰胺的药学上可接受的盐及其晶型，以及它们的药物组合物、制备方法和应用。

USPTO Abstract

本发明涉及化合物的盐及其晶型。更具体地，本发明属于药学领域，提供了化合物4‑氯‑3‑(2‑(2‑((4‑((3S,5R)‑3,5‑二甲基哌嗪‑1‑基)苯基)氨基)嘧啶‑5‑基)乙基)‑5‑甲氧基‑N‑甲基苯甲酰胺的药学上可接受的盐及其晶型，以及它们的药物组合物、制备方法和应用。

Drugs covered by this patent

infigratinib-phosphate (INFIGRATINIB PHOSPHATE)

Patent Metadata

Patent number: CN119462616A
Jurisdiction: CN
Classification: —
Expires: 2025-02-18
Drug substance claim: No
Drug product claim: No
Assignee: Hutchmed Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.